Comparing NAD precursors to improve vision in glaucoma patients
Comparisons of Nicotinamide Adenine Dinucleotide (NAD) Precursors for Neuroenhancement in Glaucoma Patients
This study is testing whether different oral supplements can help improve vision in adults with glaucoma.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 138 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Wong Chuk Hang) |
| Trial ID | NCT06991712 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effects of different oral supplements of nicotinamide adenine dinucleotide (NAD) precursors on visual function in adults with primary open-angle glaucoma. Participants will be randomly assigned to receive one of four NAD precursors or a placebo for two weeks, with assessments of visual field sensitivity and plasma NAD+ metabolite profiles conducted before and after treatment. The study aims to determine if any of the NAD precursors lead to significant improvements in visual function compared to placebo. Additionally, secondary objectives include measuring nerve fiber layer thickness and analyzing correlations between NAD+ metabolite levels and visual improvements.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with primary open-angle glaucoma who meet specific visual and intraocular pressure criteria.
Not a fit: Patients with conditions that may cause visual field loss other than glaucoma or those with a history of abnormal liver function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic approach to enhance visual function in glaucoma patients.
How similar studies have performed: While the use of NAD precursors is a novel approach in glaucoma treatment, similar studies have shown promise in other conditions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * glaucoma patients * age ≥ 18 years * best corrected VA ≥20/40 * IOP \<21 mmHg * visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard Exclusion Criteria: * pathological myopia * diseases that may cause visual field loss or optic disc abnormalities other than glaucoma * inability to perform reliable visual field * suboptimal quality of OCT images * diabetic retinopathy/maculopathy * history of abnormal liver function within 12 months * known allergy to NAD precursor supplement(s) * pregnancy or lactation * use of NAD precursor supplements 14 days prior to baseline.
Where this trial is running
Wong Chuk Hang
- HKU Eye Centre — Wong Chuk Hang, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Christopher Kai-shun LEUNG, MD — The University of Hong Kong
- Study coordinator: Christopher Kai-shun LEUNG, MD
- Email: cleung21@hku.hk
- Phone: (852)3910-2673
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.